Poola Nagaraju R, Bhuiyan Dider, Ortiz Stephan, Savant Ishani A, Sidhom Madiha, Taft David R, Kirschenbaum Harold, Kalis Michelle
Division of Pharmaceutics and Industrial Pharmacy, Long Island University, Brooklyn, New York, USA.
J Pharm Pharm Sci. 2002 May-Aug;5(2):135-45.
The HPLC method utilized a base deactivated, 5 micro, C18 column and a mobile phase containing acetonitrile (24%) and 0.025 M monobasic phosphate buffer, pH 3.2 (76%). Mobile phase flow rate and UV detection wavelength were 1 mL/min and 270 nm, respectively. Sulfadiazine (SDZ) was used as the internal standard. The method was used to measure pentamidine in perfusate and urine samples generated from studies with the isolated perfused rat kidney (IPK) model. Perfusion experiments were conducted in the presence of two different GFR markers: creatinine and inulin (PTM dose 800 micro g). Both creatinine and inulin were assayed using colorimetric methods.
The HPLC assay is rapid, sensitive and reproducible. The method was validated over two standard concentration ranges: 0.1 to 1 micro g/mL, and 1 to 10 micro g/mL. In control (drug-naïve) IPK perfusions, creatinine clearance was approximately 15% greater than inulin clearance (0.80+/- 0.21 mL/min vs. 0.69+/-0.17 mL/min, p > 0.05). In the presence of PTM, however, creatinine clearance was reduced to 0.56+/-0.27 (p < 0.05 compared to control). Inulin clearance was not altered by PTM administration (0.76+/-0.26 mL/min). Cumulative urinary excretion of PTM (% dose) was 3.0+/-0.47% and 9.6+/-4.2% in the presence of creatinine and inulin, respectively. PTM clearance was significantly reduced (0.06+/-0.01 mL/min vs. 0.13+/-0.01 mL/min, p < 0.05) and % kidney accumulation significantly enhanced (66+/-4.7% vs. 37+/-9.7%, p < 0.05) by creatinine.
Creatinine overestimated GFR in the IPK. The altered renal excretion of PTM by creatinine is consistent with inhibition of PTM tubular secretion. Because of increased kidney accumulation, detrimental effects of PTM on renal function were observed. Based on these findings, creatinine should be used cautiously as an indicator of GFR in IPK experimentation.
高效液相色谱法使用一根5μm的碱钝化C18柱和一种流动相,该流动相包含乙腈(24%)和0.025M磷酸二氢盐缓冲液,pH值为3.2(76%)。流动相流速和紫外检测波长分别为1mL/min和270nm。磺胺嘧啶(SDZ)用作内标。该方法用于测量来自离体灌注大鼠肾脏(IPK)模型研究产生的灌注液和尿液样本中的喷他脒。在两种不同的肾小球滤过率标志物存在的情况下进行灌注实验:肌酐和菊粉(PTM剂量800μg)。肌酐和菊粉均采用比色法测定。
高效液相色谱测定法快速、灵敏且可重复。该方法在两个标准浓度范围内得到验证:0.1至1μg/mL和1至10μg/mL。在对照(未用药)的IPK灌注中,肌酐清除率比菊粉清除率大约高15%(0.80±0.21mL/min对0.69±0.17mL/min,p>0.05)。然而,在存在PTM的情况下,肌酐清除率降至0.56±0.27(与对照相比,p<0.05)。给予PTM后菊粉清除率未改变(0.76±0.26mL/min)。在存在肌酐和菊粉的情况下,PTM的累积尿排泄率(%剂量)分别为3.0±0.47%和9.6±4.2%。肌酐使PTM清除率显著降低(0.06±0.01mL/min对0.13±0.01mL/min,p<0.05),并且使肾脏累积率显著提高(66±4.7%对37±9.7%,p<0.05)。
在IPK中肌酐高估了肾小球滤过率。肌酐对PTM肾脏排泄的改变与PTM肾小管分泌的抑制一致。由于肾脏累积增加,观察到了PTM对肾功能的有害影响。基于这些发现,在IPK实验中应谨慎使用肌酐作为肾小球滤过率的指标。